• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat.

    Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transformation through organic growth and acquisitions. The company was acquired by Boston Scientific in 2019. Earlier in her career, she held several leadership positions at Baxter Healthcare, most recently as President of Biopharmaceuticals Europe.

    "Dame Louise has a proven track record of success in the life sciences industry, and we are excited to welcome her to the Avantor Board of Directors," said Jonathan Peacock, Chairman of the Avantor Board. "Her addition further demonstrates Avantor's commitment to ensuring we have a diverse Board, with the right mix of skillsets and experience to drive innovation across our portfolio, advance our mission, and create long-term shareholder value."

    "It is an honor to join the Avantor Board of Directors, and I look forward to working closely with the board and executive team to further strengthen the company's position as a leader in the life sciences and advanced technologies industries," said Dame Louise. "Avantor's global reach, innovative products, and services uniquely position it to drive advancements at every stage of the scientific journey and deliver differentiated value to its many stakeholders."

    "Dame Louise is an excellent addition to our Board. I welcome her insights and expertise as we continue to execute our strategic plan to drive long-term growth and value creation," said Michael Stubblefield, Avantor President and Chief Executive Officer.

    Dame Louise currently serves as non-executive chair of the Halma plc Board of Directors and has served as a Non-Executive Director on the Boards of Premier Foods plc, Intertek Group plc, Woodford Patient Capital Trust, Atotech Ltd., and Theramex Ltd. She was also a Trustee of The Outward Bound Trust for 10 years and Chair of the 1851 Trust for five years.

    Dame Louise is an Honorary Fellow of St John's College, Cambridge. She holds both a master's degree in natural sciences and a Ph.D. in material sciences from the University of Cambridge and earned an MBA from The Open University in Milton Keynes, England. She became a Dame Commander of the Order of the British Empire in 2014.

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

    Global Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected]

    Investor Relations Contact

    Christina Jones

    Vice President, Investor Relations

    Avantor

    805-617-5297

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/avantor-appoints-dame-louise-makin-dbe-phd-to-its-board-of-directors-302297011.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/27/25 4:58:03 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/22/25 5:37:34 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/9/25 4:51:58 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avantor® to Host Second Quarter 2025 Earnings Call on Friday, August 1, 2025

      RADNOR, Pa., June 27, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the

      6/27/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

      RADNOR, Pa., May 16, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Brent Jones, Executive Vice President and Chief Financial Officer, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20, 2025 at approximately 8:00 a.m. Eastern Time.  To view the presentation slides and to hear a live audio webcast of the session, visit Events & Presentations in the I

      5/16/25 8:30:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

      RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time.  To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience

      5/2/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avantor downgraded by Goldman with a new price target

      Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

      4/29/25 8:05:35 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by TD Cowen with a new price target

      TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

      4/28/25 8:32:10 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by Stifel with a new price target

      Stifel downgraded Avantor from Buy to Hold and set a new price target of $14.00

      4/28/25 8:31:49 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    SEC Filings

    See more
    • SEC Form SD filed by Avantor Inc.

      SD - Avantor, Inc. (0001722482) (Filer)

      5/30/25 4:37:48 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      5/12/25 5:16:45 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      4/28/25 8:29:56 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Laboratory Solutions Walker Corey covered exercise/tax liability with 2,730 shares, decreasing direct ownership by 1% to 231,271 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      6/24/25 5:20:19 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/27/25 4:58:03 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/22/25 5:37:34 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials